Tarsus Pharmaceuticals, Inc. (TARS)
TARSNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$70.84
0.0000 (0.00%) today
Pre-market, Nov 9, 4:00 PM ET
- Market cap
- $3.49bn
- P/E
- –
- EPS, last 4 quarters
- $-1.57
- Dividend yield
- –
- Day range
- –
- 52-week range
- $53.89 to $91.53
- Average volume
- 914.5k
- Previous close
- $70.84
Analysts
10 coveringBuy10 buy, 0 hold, 0 sell
Targets a year out average $105.57, +49.0% from here
Earnings
next estimate $-0.3900Next report
Dec 2025
-5.3%
Mar 2026
+65.2%
Jun 2026
-104.8%
Sep 2026
+45.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $151.67m | $162.05m | $173.91m | $194.57m |
| Gross profit | $140.74m | $152.66m | $161.80m | $180.68m |
| Operating income | -$7.98m | -$6.12m | -$19.91m | -$662.09m |
| Net income | -$8.37m | -$6.97m | -$18.55m | -$668.33m |
Last four quarters: revenue $682.20m, margin -102.9%, free cash flow $32.44m
News
8 latest- HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix GrowthZacks · 5 days ago
- Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock RisesZacks · 5 days ago
- Tarsus (TARS) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock UpZacks · 6 days ago
- CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y RevenuesZacks · 6 days ago
- Tarsus Pharmaceuticals Q3 Net Loss Widens To $668 Mln On Acquisition Costs As XDEMVY Sales Grow RTTNews · 6 days ago
- Tarsus Pharmaceuticals Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- Tarsus Pharmaceuticals, Inc. Reports Record XDEMVY Net Product Sales of $194.6 million in Third Quarter 2026Fintel · 6 days ago
The company
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea, TP-05 as an oral tablet for the potential prevention of Lyme disease, IRX-101 for potential use as an ocular antiseptic and gildeuretinol for the potential treatment of Stargardt disease.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- tarsusrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.